Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Investing Activities: 2015-2024

Historic Cash from Investing Activities for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Dec 2024 value amounting to -$48.2 million.

  • Rhythm Pharmaceuticals' Cash from Investing Activities fell 171.25% to -$246.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$146.3 million, marking a year-over-year decrease of 213.44%. This contributed to the annual value of -$48.2 million for FY2024, which is 750.36% down from last year.
  • According to the latest figures from FY2024, Rhythm Pharmaceuticals' Cash from Investing Activities is -$48.2 million, which was down 750.36% from -$5.7 million recorded in FY2023.
  • Rhythm Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $158.5 million during FY2020, with a 5-year trough of -$62.2 million in FY2021.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$5.7 million (2023), whereas its average is -$8.6 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 666.79% in 2020, then tumbled by 750.36% in 2024.
  • Over the past 5 years, Rhythm Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $158.5 million in 2020, then tumbled by 139.21% to -$62.2 million in 2021, then skyrocketed by 145.09% to $28.0 million in 2022, then slumped by 120.21% to -$5.7 million in 2023, then tumbled by 750.36% to -$48.2 million in 2024.